Searched for
DRL
Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...- Reddy Pharma loses 'name' in Delhi HC rulingThe Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...
- Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...
- Should you buy the dip? Strategist Anand James shares his weekly stock strategyMarket expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...
- Market Outlook: Rupak De’s top 3 trading stock picks for the week aheadGeopolitical tensions, rising crude oil, and a weakening rupee are fueling market volatility, according to Rupak De of LKP Securities. He n...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- What CLSA says on Lupin; Morgan Stanley on DRL, Godrej ConsumerIn the case of DRL, Morgan Stanley said that the drug maker continued to deliver granular growth and that the growth trend should continue ...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- US turnaround drives DRL’s stellar Q4 showDRL’s strategy pivot, with focus on the core areas of US generics, India and emerging markets, has been yielding results.
- Sell DRL Ltd with a target of Rs 2510: Sandeep WagleDRL Ltd is a ‘SELL’ call with a target of Rs 2510 and a stop loss of Rs 2690.
- Genzyme Corporation files patent infringement suit against DRLMozobil (plerixafor injection) is a hematopoietic stem cell mobiliser indicated to patients with non-Hodgkin's lymphoma (blood cancer) and ...
- Brokerages raise price target on Dr Reddy's to as high as Rs 2,720 on FDA nodBrokerages see the FDA approval to Dr Reddy’s Laboratories (DRL) for generic Vidaza as a positive for the company.
- Fresenius files patent infringements suit against DRL in USFresenius Kabi has dragged leading pharmaceuticals company Dr Reddy's to court for allegedly infringing on the former's patented anaestheti...
- Bristol-Myers sues Dr Reddy's Laboratories for patent infringement in USBristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories over the cancer drug Ixempra.
- Dr Reddy's starts Phase-II trials of DRL-17822 moleculePhase-II clinical trials are conducted on a larger sample of human subjects (20-300) to assess how well a drug works.
- DRL faces patent suit in US over allergy genericNYSE-listed Dr Reddy’s Laboratories (DRL) is embroiled in a fresh patent infringement row with US-based drug-discovery firm Albany Molecula...
- DRL seeks USFDA help to make cancer drug cloneUS-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.
- Dr Reddy's looks at settling Sanofi dispute out of courtPharma major Dr Reddy’s Laboratories (DRL) is contemplating an out-of-court settlement with the French company Sanofi-Aventis for anti-alle...
- DRL, Novartis smoke peace pipe on Alzheimer's drugDr Reddy’s Laboratories (DRL) has entered a settlement agreement with Novartis Pharma to suspend the launch of its generic capsule rivastig...
- DRL expects verdict in Aciphex case by May 15As the patent clash between Dr Reddy's Labs (DRL) and Japanese pharma firm Eisai for the control over $1.3-billion anti-ulcer drug Aciphex ...
Load More
